Treace Medical Concepts Inc (NAS:TMCI)
$ 8.55 -0.23 (-2.62%) Market Cap: 532.64 Mil Enterprise Value: 534.29 Mil PE Ratio: 0 PB Ratio: 5.06 GF Score: 40/100

Treace Medical Concepts Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 11:45PM GMT
Release Date Price: $13.46 (+6.57%)
Robbie Marcus JPMorgan;Analyst

Good afternoon, everyone. I'm Robbie Marcus, medtech analyst at JPMorgan. Really happy to introduce our next session. John Treace, the CEO of Treace Medical. John, I'll hand it over to you and then we'll do some Q&A.

John Treace Treace Medical Concepts
Inc. - CEO, Founder & Board Member

Right, great. Thanks. Thanks, Robbie, and good afternoon, everyone. Thanks for joining us here today. It's great to be at the JPMorgan Healthcare Conference and have the opportunity to talk about Treace Medical.

Since our IPO in 2021, we've continued to execute on our strategic plan, resulting in US growth of 32% during 2023, encouraging EBITDA progress and continued gains in our operating metrics, reaffirming once again, we have the right strategies in place to expand the market penetration of our differentiated technologies.

Safe Harbor disclosure here. Please refer to our website. Our non-GAAP reconciliations are also on the website.

So Treace Medical is a high-growth medtech company focused on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot